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1.1 CD40 and CD154 
CD40 is a cell surface receptor which was first identified and functionally 
characterized in B-lymphocytes. Its ligand, CD154 (CD40L, gp39, T-BAM or 
TRAP), is mainly expressed on activated CD4+ T cells (van Kooten et al. 2000, 
Schoenbeck et al. 2001). Both CD40 and CD154 belong to an emerging receptor-
ligand family that includes the TNF receptor and TNF family, respectively. This 
family is characterized by structural homologies, clustered chromosome location, 
shared signal transduction pathways and overlapping biological activities in 
processes such as cell growth, differentiation and programmed cell death.  
 
1.1.1 Expression of CD40 and CD154 
CD40 is principally expressed on B-cells and professional antigen-presenting cells 
(APCs), like dendritic cells and monocytes. Recently, it has become clear that 
CD40 is expressed much more broadly, including endothelial cells, vascular 
smooth muscle cells and fibroblasts (van Kooten et al. 2000, Schoenbeck et al. 
2001). Although CD40 expression is generally low in these cells, the protein is 
clearly up-regulated under various pathological conditions. The combination of 
TNF-α and INF-γ has been shown to be the most potent stimulus for CD40 
expression. Research in our group has shown that activation of signal transducer 
and activator of transcription-1 (STAT-1) is crucial for the cytokine-induced 
expression of CD40 in rat vascular smooth muscle cells as well as in human 
endothelial cells (Krzesz et al. 1999, Wagner et al. 2002). With regard to the latter, 
however, STAT-1 mediates CD40 expression either directly or indirectly through de 
novo synthesis of interferon regulatory factor-1 (IRF-1). 
The expression of CD154 on activated T-cells is transient and tightly regulated. 
CD154 expression can be seen on a subset of CD4+ memory T-cells as early as 5-
15 minutes after APC-induced activation through the T-cell receptor complex 
(Casamayor-Pellejia et al. 1995). Such surface expression does not require de 
novo protein synthesis and is probably due to preformed CD154. A second wave 
of CD154 expression, preceded by an increase in the RNA level, occurs 1-2 hours 
after activation, reaches the peak after 6-8 h and gradually declines thereafter. 
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This transient expression help to ensure that CD154 expression remains restricted 
in time. Moreover, CD154 expression has also been detected on CD8+ T-cells, B-
cells, NK cells, monocytes and dendritic cells under certain conditions (van Kooten 
et al. 2000, Schoenbeck et al. 2001). Especially, it has recently been reported that 
platelets express CD154 within seconds of thrombin activation in vitro and in the 
process of thrombus formation in vivo (Henn et al. 1998). In addition, despite the 
membrane-bound form (protein of 32 - 33 kDa), there are two shorter versions of 
CD154 (31 kDa and/or 18 kDa). These shorter soluble forms retain their ability to 
form trimers to bind CD40, and to transduce biological signals (Graf et al. 1995, 
Mazzei et al. 1995). This indicates that CD154 might also act as a bona fide 
cytokine. Qualitative differences between the soluble and membrane-bound forms 
may exist, too. 
 
1.1.2 CD154/CD40 interactions in immune responses 
CD154 interacts with CD40 expressed on B-cells, macrophages, dendritic cells, 
fibroblasts and endothelial cells to induce and regulate immune responses. The 
important biological role of CD154/CD40 interactions has been firmly established. 
In vivo, deletion or mutations of either the CD40 or CD154 gene leads to severe 
immunodeficiency, in both man and mouse, characterized by hyper-IgM syndrome 
(HIGM) as well as T-cell defects in cell-mediated immunity (Castigli et al. 1994, 
Renshaw et al. 1994, Razanajaona et al. 1996).  
For humoral immunity: CD40 emerges early on CD34+ B-cell precursors in the 
bone marrow before immunoglobin gene rearrangement. It is expressed on B-cells 
until their terminal differentiation into plasma cells. Direct effects of CD40 
activation on B-cells include cytokine production (IL-6, IL-10, TNF-α, LT-α), 
expression of adhesion molecules and costimulatory receptors (ICAM-1, CD23, 
CD80, CD86) and increased expression of MHC I and MHC II (Khanna et al. 1997, 
Dadgostar et al. 2002). These molecules all contribute to the biological function of 
B-cells. Extensive in vitro studies have demonstrated that CD40 activation has 
major effects on many steps of the B-cell nature history, including rescue from 
apoptosis, differentiation into germinal center cells, Ig isotype switching and 
maturation into memory cells (Kehry 1996, Klaus et al. 1997). Considering the key 
role of the CD154/CD450 pathway in antibody formation, it is evident that blockade 
of this pathway may provide a novel means of inhibiting pathogenic auto-
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antibodies or unwanted antibodies that may arise during the exogenous 
administration of foreign antigens. 
For cellular immunity: CD154-induced triggering of CD40 on the surface of other 
APCs including dendritic cells and macrophages may ultimately control both the 
afferent phases of immune recognition by T-cells as well as important effector 
mechanisms of cell mediated immunity (Grewal 1998, van Kooten et al. 2000). 
CD40 activation augments the antigen presenting functions of dendritic cells by 
inducing maintenance of high levels of MHC class II antigens and marked 
upregulation of accessory molecules including CD58. In addition, CD40 activation 
also induces the expression of key co-stimulatory molecules CD80 (B7-1) and 
CD86 (B7-2). Through interaction with CD28, they provide the essential second 
signal required for full T-cell activation. In the absence of CD80/CD86 triggering of 
CD28, anergy or tolerance rather than T-cell activation ensues as a consequence 
of antigen triggering. These data suggest that the CD154/CD40 pathway governs 
the T-cell decision whether immunity or tolerance is developed in response to 
exogenous antigens. In this regard, recent in vivo studies in mice strongly suggest 
that antibody-based blockade of CD154/CD40 interactions induces tolerance. For 
example, the anti-CD154 mAb (MR1) alone has allowed indefinite islet allograft 
survival in recipient mice and significantly inhibits heart, skin and kidney allograft 
rejection (Reul et al. 1997, Larsen et al. 1997, Elwood et al. 1998). 
In addition to up-regulating co-stimulatory molecules, CD154/CD40 interactions 
also induce APCs to secrete an important set of cytokines and chemokines 
including IL-12, IL-8, TNF-α and MIP-1α (Kiener et al. 1995, Cella et al. 1996). The 
effect of CD40 ligation on IL-12 secretion is of interest because IL-12 itself up-
regulates CD154 expression on T-cells and synergizes with IL-2 as well as with 
other co-stimulatory molecules, including CD80 and CD86, to maximize CD154 
expression (Peng et al. 1998). It is well known that IL-12 functions as a major 
cytokine governing the differentiation of CD4+ T-cell subsets by promoting the 
differentiation of the Th1 subset. Moreover, it has been shown that CD154/CD40 
interactions are crucial for the IL-12-dependent priming of Th1-cells in vivo (Kelsall 
et al. 1996). Blockade of the CD154/CD40 pathway prevents a variety of immune 
disorders in mice mediated by CD4+ Th1-cells including type I collagen-induced 
arthritis, experimental autoimmune encephalitis and the NOD model of diabetes 
mellitus (Desai-Mehta et al. 1996, MacDonald et al. 1997, Markees et al. 1999). 
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1.1.3 CD154/CD40 interaction in endothelial cells 
As noted above, CD40 expression is generally low in endothelial cells, but clearly 
up-regulated under pro-inflammatory conditions, especially by the combination of 
TNF-α plus INF-γ. As the site for leukocyte adhesion and extravasation, the 
endothelium plays an important role in chronic inflammatory diseases. Likewise, 
CD154/CD40 interactions between activated T-cells and endothelial cells are in 
concert with other ligand-receptor interactions and cytokine release (Fig. 1). A 
series of studies have demonstrated that CD40 activation induce endothelial cells 
to express ICAM-1, VCAM-1 and E-selectin (Hollenbaugh et al. 1995, Karmann et 
al. 1995). These adhesion molecules are involved in the binding of inflammatory 
cells to the endothelium and the subsequent emigration of these cells to the site of 
inflammation. Functional studies have provided further evidence that blockade of 
CD154/CD40 interaction will retard migration of leukocytes through endothelial cell 
barriers. In this regard, anti-CD154 antibodies have been shown to effectively 
block the appearance of pro-inflammatory cells at the site of inflammation in a 
variety of animal models of autoimmunity.  
Moreover, CD154/CD40 interaction on the surface of endothelial cells induces 
secretion of tissue factor, as well as the release of cytokines and chemokines (IL-
6, IL-8, IL-12 and MCP-1) (Millar et al. 1998). All of these will facilitate the 
recruitment and activation of more leucocytes. Interestingly, CD154 is the most 
potent stimulus for endothelial cells to release IL-12, since TNF-α, which belongs 
to the same superfamily as CD154, has no such effect. The CD154 stimulated IL-
12 release can be further enhanced by IFN-γ, a typical Th1 cytokine (Lienenlueke 
et al. 2001). Therefore, a positive feed-forward loop seems to exist between 
leukocytes and endothelial cells, and CD154/CD40 interactions may play a pivotal 
role in this process. In addition to expressing CD40, as noted above, endothelial 
cells also have been reported to express CD154. Although the precise biological 
function of CD154 expressed on the endothelial cell surface is not known, it is of 
major interest that blockade of the CD154/CD40 pathway exerts a profound 




Figure 1. CD154/CD40 mediated interactions between activated T-cell, 
monocyte and endothelial cell. The activation of endothelial cell by CD154 is associated 
with an increase in activity of a variety of other ligand-receptor interactions and the 
release of cytokines, especially IL-12. This indicates that CD154/CD40 interactions drive a 
positive pro-inflammatory feed-forward loop between these cells. (EC: endothelial cell, 
SMC: smooth muscle cell, TF: transcription factor) 
 
 
1.2 Inflammatory bowel disease 
Inflammatory bowel disease (IBD), mainly including Crohn’s disease and ulcerative 
colitis, is characterized by chronic inflammation of the gastrointestinal tract with 
variable location, extent and pathological features (Sartor 1997, Fiocchi 1998, 
Podolsky 2002). Patients with IBD often lose weight and experience a change on 
bowel habits, mostly diarrhea. They also experience cramping abdominal pain, 
fever, joint pain and skin lesions. In industrialized nations of the western 
hemisphere, approximately 0.2% of the population develops IBD. However, the 
etiology of IBD remains unknown up to now and further study is necessary to 
provide efficient therapy. 
 
1.2.1 Clinical pathology of IBD 
Crohn’s disease is an inflammation that extends into the deeper layer of the 
intestinal wall. It is found most often in the ileum and the cecum, which is 
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sometimes referred to as the ileocecal region. However, it can develop in any part 
of the gastrointestinal tract, including the anus, stomach, esophagus, and even the 
mouth. Crohn’s disease may affect the entire colon or form a string of continuous 
ulcers in one part of the colon or develops as multiple scattered clusters of ulcers 
skipping healthy tissue in between. Unlike Crohn’s disease, ulcerative colitis is an 
inflammatory disease of the large intestine. It is characterized by a more 
superficial, continuous inflammation that affects the inner lining or mucosa of the 
colon. The inflammation is usually most severe in the sigmoid and rectum and 
diminishes higher in the colon. The disease develops uniformly and consistently 
until, in some cases, the colon becomes rigid and foreshortened. Both diseases 
increase the risk of developing bowel cancer and cause a greatly diminished 
quality of life in affected individuals, which mostly lasts throughout their disease. 
 
1.2.2 The important role of the immune system in chronic IBD 
In Crohn’s disease, it was found that the mucosa of the affected patients is 
dominated by CD4+ lymphocytes with a Th1-type, characterized by the production 
of IFN-γ and IL-2. In contrast, the mucosa in patients with ulcerative colitis is 
dominated by Th2-cells, characterized by the production of transforming growth 
factor-β (TGF-β) and IL-5 but not IL-4 (Neurath et al. 2002). This is not to say that 
Th2 cytokines are not present in Crohn’s disease and that Th1 cytokines are not 
present in ulcerative colitis, but there appears to be a polarization of one group of 
cytokines over the other. In fact, activation of these central immune cells is 
eventually accomplished by the production of a wide variety of nonspecific 
mediators of inflammation. These mediators enhance the inflammatory process 
itself and tissue destruction, which ultimately results in the clinical manifestation of 
disease. 
In IBD, chronic recurrent intestinal inflammation appears to derive from stimulation 
of the mucosal immune system by products of commensal bacteria in the lumen 
(Fig. 2). Stimulation may occur as a result of the penetration of bacterial products 
through the mucosal barrier, leading to their direct interaction with immune cells, 
especially dendritic cells and lymphocyte populations, to promote a classic 
adaptive immune response. Alternatively, bacterial products may stimulate the 
surface epithelium, possibly through receptors that are components of the innate 
immune-response system. The epithelium can, in turn, produce cytokines and 
6
Introduction
chemokines that recruit and activate mucosal immune cells. Activation of classic 
antigen-presenting cells, such as dendritic cells, or direct stimulation through 
pattern-recognition receptors promotes the differentiation of Th1-cells in patients 
with Crohn’s disease (shown here) or possibly, atypical Th2-cells in patients with 
ulcerative colitis. The stereotypical cytokines activate macrophages which in turn 
produce IL-12 and IL-18 and thus further stimulate Th1-cells in a self-sustaining 
cycle. In addition, the activated macrophages also produce a potent mix of pro-
inflammatory cytokines including IL-1, IL-6 and most notably TNF-α, which activate 
a broad variety of other immune cells. All of these will destroy the balance between 
anti-inflammatory and pro-inflammatory cytokines in the mucosa and finally lead to 
an inappropriate and sustained activation of the mucosal immune system.  
 
Figure 2.  Pathogenesis of IBD.  
 
Therefore, IBD might result from defects in both the barrier function of the 
intestinal epithelium and the mucosal immune system. Genetic and environmental 
factors may be involved with the abnormal immune response as the ultimate 
result. Advances in the understanding of the mediators involved in this process, 
even if still incomplete, have lead to great interest in the evaluation of a variety of 
new therapeutic agents with novel actions such as anti-TNF-α, IL-10, anti-α4 
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integrin, anti-IL12, anti-CD154 and anti-ICAM-1 (Rutgeerts 2002, Rijcken et al. 
2002, Jong et al. 2000). As noted above, the chronic inflammatory response in 
Crohn's disease is thought to be mediated by Th1-cells and CD154/CD40 
interaction is crucial for the in vivo priming of Th1-cells through stimulation of IL-12 
secretion by APCs. In addition, CD154/CD40 interaction also contributes to the 
enhanced expression of adhesion molecules on endothelial cells, which is 
especially important in maintaining inflammation. Considering all of these, 
blockade of CD154/CD40 interaction may have plausible therapeutic effects for 
Crohn’s disease. 
 
1.3 Aims of the work 
Based on the immune-regulatory features of CD154/CD40 interaction and its role 
in the pathogenesis of autoimmune diseases, interfering with this costimulation 
has been considered to exert pronounced therapeutic effects. Although 
administration of anti-CD154 antibodies has been demonstrated to effectively 
inhibit inflammatory responses in a variety of animal models, adverse side effects 
observed both in experimental animals and in patients may limit their use in the 
treatment of chronic inflammatory diseases. Suppression of CD40 expression in 
CD154 target cells may thus provide a feasible therapeutic alternative. In this 
study, the possibility of interfering with CD154/CD40 interactions by using CD40 
antisense ODNs was investigated both in vitro and in vivo. 
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2. Materials and methods 
2.1 Elucidation of the rat CD40 mRNA sequence 
Depending on the partial sequence of the rat CD40 mRNA, the Rapid Amplification 
of cDNA Ends (RACE) method was employed to elucidate the coding sequence of 
its 5' -end including the transcription start site. It is a procedure for amplification of 
nucleic acid sequences from a messenger RNA template between a defined 
internal site and unknown sequences. An overview of the procedure is shown in 
Fig. 3. The 5’-RACE kit, (Life Technologies, Karlsruhe) was used for these 
experiments.  
 
Figure 3. Overview of the 5’-RACE procedure. 
 
The sequences of abridged anchor primer (AAP), abridged universal amplification 
primer (AUAP) and rat CD40 gene specified primers (rGSP) were as follows: 
AAP:  5’-GGCCACGCGTCGACTAGTACGGGIIGGGIIGGGIIG –3’ 
AUAP: 5'-GGCCACGCGTCGACTAGTAC -3' 
rGSP1: 5‘-ATCCTCACAGCTTGTCCA-3‘ 
rGSP2: 5’-ACATGCCTCGCAATCCTT GC-3’ 
rGSP3: 5’-GAGGCAAAGACACCAT-3’ 
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2.1.1 Total RNA extraction from animal tissue 
Total RNA was isolated by Rneasy Mini Kit (Qiagen, Germany). Rat spleen was 
freshly removed from sacrificed animals, and immediately frozen in liquid nitrogen. 
With a mortar and pestle, tissues were grinded thoroughly in liquid nitrogen. The 
tissue powder (about 20 mg) was lysed in 350 µl buffer RLT and homogenized by 
5 times passing through a 20-gauge needle. Then, 350 µl 70% ethanol were 
added and mixed immediately by pipetting. The mixture (about 700 µl) was applied 
to an Rneasy mini column to bind the RNA by centrifugation at 13,000 rpm for 15 
s. The column was washed once with 700 µl buffer RW1, and twice with 500 µl 
buffer RPE. After the last washing step, an additional centrifugation at 13,000 rpm 
for 1 min was performed to dry the membrane. RNA was eluted into 40 µl RNase-
free water and kept at -70°C. 
 
2.1.2 First strand cDNA synthesis 
Total RNA isolated from rat spleen (~5 µg) was mixed with 2.5 pmol rGSP1 (1 
pmol/µl) in a total volume of 15.5 µl. The mixture was incubated 10 min at 70°C to 
denature RNA, then chilled 1 min on ice. After a brief centrifugation, it was mixed 
with 9.5 µl first strand cDNA synthesis mix [20 mM Tris/HCl (pH 8.4); 50 mM KCl; 
2.5 mM MgCl2; 10 mM DTT; 0.4 mM dNTP and 200 U SUPERSCRIPTTM II RT, final 
concentration] and incubated for 50 min at 42°C. The reaction was terminated by 
incubation at 70°C for 15 min. Subsequently, the sample was treated with 1 µl of 
RNase mix, a mixture of RNase H and RNase T1, at 37°C for 30 min to degrade 
the RNA. The sample was kept on ice until the purification step. 
 
2.1.3 Purification of cDNA 
Excess nucleotides and rGSP1 must be removed from the first strand product. 
Otherwise, the large amount of rGSP1 relative to cDNA product will influence the 
tailing step. The sample was mixed with 120 µl of binding solution (6M NaI) and 
transferred to a GlassMAX spin cartridge. cDNA was bound to the column by 
centrifugation at 13,000×g for 20 s. The column was washed four times with 400 µl 
of pre-chilled 1×washing buffer (4°C) and two times with 400 µl of pre-chilled 70% 
ethanol (4°C). After removing the final 70% ethanol wash from the tube, an 
additional centrifugation at 13,000×g for 1 min was performed to dry the column. 
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The purified cDNA was recovered in 50 µl sterilized water (pre-heated to 65°C). 
 
2.1.4 TdT tailing of cDNA 
Purified cDNA sample (10 µl) was mixed with 14 µl tailing mix [10 mM Tris/HCl (pH 
8.4); 25 mM KCl; 1.5 mM MgCl2; 200 µM dCTP, final concentration]. The mixture 
was incubated for 3 min at 94°C and then cooled down for 1 min on ice. After a 
brief centrifugation, 1 µl TdT was added to the mixture and incubated for 10 min at 
37°C. The reaction was terminated by heating for 10 min at 65°C. The dC-tailed 
cDNA was stored at -20°C. 
 
2.1.5 PCR of dC-tailed cDNA 
The first PCR amplification of the rat CD40 cDNA was performed with primers of 
AAP and rGSP2. To get rid of the possible mismatching, pfu DNA polymerase was 
used in the reaction. dC-tailed cDNA (5 µl) was mixed with 45 µl PCR Mix [20 mM 
Tris/HCl (pH 8.4); 50 mM KCl; 1.5 mM MgCl2; 200 µM dNTP, 400 nM rGSP2, 400 
nM AAP, 2.5 U pfu, final concentration]. PCR parameters were as follows: pre-
denaturation at 94°C for 2 min; denaturation at 94°C for 30 sec, annealing at 55°C 
for 1 min and extension at 76°C for 2 min (35 cycles); final extension at 76°C for 
10 min. 
Subsequently, a nested PCR was performed with primers of rGSP3 and AUAP, 
using the dilution of the first PCR product (1:1000) as a template. PCR was 
programmed as described above. PCR products were checked in 1% agarose gel 
with ethidium bromide staining. 
 
2.1.6 Purification of PCR product from agarose gel 
The DNA fragment was excised from the gel and purified with QIAEX II kit 
(Qiagen, Germany). Three volumes of binding and solubilization buffer (QX1) and 
10 µl QIAEX II solution were added to 1 volume of gel. To bind DNA, the solution 
was incubated at 50°C for 10 min with occasionally vortexing. After centrifugation 
at 13,000×g for 30 sec, the pellet was washed once with QX1 buffer and once with 
PE buffer. After removing the washing buffer of the last step, the pellet was 
completely dried at room temperature (for about 15 min). Then, the pellet was 
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resuspended in 20 µl H2O and incubated for 5 min at room temperature. After 
centrifugation at 13,000×g for 1 min, the supernatant, which contains the DNA 
fragments, was collected into a new tube. 
 
2.1.7 Sequencing of the PCR product 
A 10 µl sequencing reaction was set up by mixing 5 µl purified PCR product (100 
ng), 3 µl BigDye Terminator DNA-sequencing-mix (Applied Biosystems, Damstadt), 
1 µl rGSP3 primer (1 pmol/µl) and 2 µl sterilized water. Sequencing-PCR was 
performed for 25 cycles as follows: denaturation at 94°C for 30 sec, annealing at 
55°C for 15 sec, extension at 60°C for 4 min. 
After the sequencing-PCR, the products were precipitated by adding 80 µl H2O,  
15 µl 2M NaAC (pH 4.0), 250 µl 100% ethanol and centrifugation at 14,000×g for  
20 min. The pellet was washed once with 250 µl 70% ethanol and then dissolved 
in 5 µl H2O. Samples were sent for sequencing reading with 3100 Genetic 
Analyser (Applied Biosystems, Damstadt). 
 
 
2.2 Cell biology methods 
2.2.1 Medium and substances for cell culture 
M199     Life Technologies   Karlsruhe 
RPMI 1640    Life Technologies   Karlsruhe 
Waymouth    Life Technologies   Karlsruhe 
HBSS     Life Technologies   Karlsruhe 
0.05% Trypsin/0.2% EDTA Life Technologies   Karlsruhe 
TES     Fluka     Buchs/Swiss 
HEPES    Roth     Karlsruhe 
Dispase    Roche Diagnostics   Mannheim 
Nystatin    Life Technologies   Karlsruhe 
Penisillin    Life Technologies   Karlsruhe 
Streptomycin    Life Technologies   Karlsruhe 
FBS (Fetal Bovine Serum)  Life Technologies   Karlsruhe 
ECGS     c.c.pro    Neustadt/W. 
(Endothelial Cell Growth Supplement) 
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Heparin    Sigma-Aldrich   Deisenhofen 
Gelatine    Sigma-Aldrich   Deisenhofen 
Ficoll-Paque®   Amersham    Freiburg 
 
2.2.2 Culture of rat vascular smooth muscle cells (rSMCs) 
Vascular smooth muscle cells were isolated from male Wistar rats as follows (200g 
body weight; Winkelmann, Borchen/Westfalen, Germany). After sacrifice of the 
animal by an overdose of pentooooo, the aorta was gently isolated and rinsed with 
Waymouth medium. After washing off the contaminating blood and completely 
removing the surrounding fat and connective tissue, the aorta was opened 
longitudinally to scrape off the endothelial cells. Then, the aorta was seized into 
small pieces (about 4 mm2), which were placed in a 60mm gelatin-coated dish 
containing 1.5 ml growth medium (Waymouth medium supplemented with 10% 
FBS, 50 U/mL penicillin, 50 µg/mL streptomycin and 1 µg/mL heparin). The aorta 
pieces were cultured under 5% CO2, at 37°C. After about 3 days, smooth muscle 
cells started to grow out of the explants which were subsequently removed. The 
cells usually formed a confluent monolayer within one week after explantation. The 
identity of the cells was confirmed by immunofluorescence staining with anti-α-
actin antibody. 
For passaging, cells were washed twice with HBSS, and then digested with 0.5% 
trypsin/0.2% EDTA for 5 min at 37°C. Trypsin was inactivated by medium 
containing 10% FBS. Cells were pelleted by centrifugation at 126×g for 5 min and 
resuspended in Waymouth medium. Cells of passage 3 were used for the 
experiments. 
 
2.2.3 Culture of human umbilical vein endothelial cells (HUVECs) 
HUVECs were isolated from freshly collected umbilical cords (less than 24 hours) 
by enzymatic digestion under sterile conditions. After cannalating the umbilical 
vein from both ends, 50 ml HBSS were passed through to get rid of remaining 
blood. Then, the vein was filled with Dispase solution (0.3%) and incubated for 30 
min at 37°C. The endothelial cells were detached from the vessel wall by gentle 
massage and collected into 50 ml Facon tubes. After centrifugation at 126×g for 5 
min, the pelleted cells were resuspended in the growth medium (M199 medium 
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containing 20% FBS, 50 U/mL penicillin, 50 µg/mL streptomycin, 10 U/mL nystatin, 
5 mM HEPES and 5 mM TES, 1 µg/mL heparin and 40 µg/mL ECGS). Cells were 
seeded in gelatin-coated 6-well plates and cultured under 5% CO2 at 37°C. 
Medium was changed on the second day to get rid of contaminating blood cells. 
Cells were grown to 90-100% confluence within 4 to 5 days.  
 
2.2.4 Culture of mouse myeloma cells 
The mouse myloma cell line P3xTB.A7 stably expressing human CD154, together 
with the non-transfected P3x63Ag8.653 control cells were gifts from Prof. R. 
Kroczek (Robert-Koch-Institute, Berlin). They were cultured in RPMI 1640 medium 
with 10% FBS under 5% CO2 at 37°C. Every three months, cells were selected 
with gentamycin (G-418 sulphate, Gibco-BRL, Life Technologies, Karlsruhe) to 
maintain expression of the transgene. 
 
2.2.5 Western blot analysis 
For Western blot analysis of CD40 expression, cells were scraped off the plate into 
1 ml HBSS and then pelleted by centrifugation at 500×g for 5 min. The cell pellet 
was resuspended in lysis buffer [50 mM Tris/HCl (pH 8.0), 150 mM NaCl, 0.1% 
SDS, 1 mM DTT, with Proteinase Inhibitor Mix, 30 µl/well] and lysed by 5 cycles of 
freeze/thawing in liquid nitrogen and at 37°C, respectively. After centrifugation at 
13000×g for 5 min, the supernatant was collected into a new tube. Protein 
concentration of cell extracts was measured with Protein Assay Buffer (Bio-Rad, 
Muenchen). 
Sample protein (30 µg) was denatured by heating to 94°C for 5 min in 1× loading 
buffer (Roth, Karlsruhe), and then separated on 12% denaturing polyacrylamide 
gel. Electrophoresis was performed at constant current (20 mA per gel) for 
approximately 2 h. Subsequently, the separated proteins were electronically 
transferred to a BioTrace polyvinylidene fluoride transfer membrane (Pall, 
Dreieich) with Mini-Trans Blot system (Bio-Rad, Muenchen) at 350 mA for 45 min.  
The membrane was blocked with 5% non-fat milk in PBS at room temperature for  
1 h followed by incubation with primary antibody at 4°C overnight. Human CD40 
was detected by using polyclonal rabbit anti-human CD40 antibody (Research 
Diagnostics, Flanders, NJ) at 1:2000 dilution. Rat CD40 was detected by using a 
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polyclonal rabbit anti-rat CD40 antibody (Biovision, Sandiego, USA) at 1:500 
dilution. HRP-conjugated goat anti-rabbit IgG antibody (Sigma, Germany) was 
used as the secondary antibody at 1:10,000 dilution. The detected bands were 
visualized by SuperSignal Chemiluminescent Substrate (Pierce, Rockford, USA) 
followed by exposure of the membrane to X-ray film (Koda, Germany) for 1 min. 
 
 
2.3               Molecular biology methods 
2.3.1 Transfection with antisense ODNs 
Cells were grown in 6-well plates to approximately 90% confluence at the time of 
transfection. For each well, 400 pmol antisense ODNs was diluted in 100 µl M199 
medium. In parallel, 2 µg Lipofectin (Life Technologies, Karlsruhe) was diluted in 
100 µl M199 medium. Both solutions were left at room temperature for 30 min. 
Thereafter, the solutions were combined and incubated at room temperature for 
another 15 min. During this time, cells were washed once with M199 medium and 
800 µl M199 medium were added in each well. The transfection mixture was 
poured onto the cells followed by gentle mixing. Cells were then incubated with the 
transfection medium for 4 h (rSMCs) or 2 h (HUVECs) in the incubator before 
changing back to the normal growth medium. 
 
2.3.2 Semi-quantitative RT-PCR  
Cells cultured in 6-well plates were washed twice with PBS before being disrupted 
by the addition of RLT buffer (350 µl/well). Total RNA was isolated as described in 
2.1.1. For each sample, 1 µg RNA was mixed with 1 µl oligo-dT(15) (500 µg/µl) in a 
total volume of 14 µl and denatured by incubation at 70°C for 10 min. After brief 
centrifugation, 6 µl cDNA-Synthesis-Mix [50 mM Tris/HCl (pH 8.3), 75 mM KCl, 3 
mM MgCl2. 10 mM DTT, 0.5 mM dNTP and 200 U MMLV RT, final concentration] 
was added and cDNA synthesis continued for 50 min in a water bath at 42°C. The 
reaction was stopped by heating to 70°C for 10 min. Each cDNA sample was 
diluted with 180 µl H2O and stored at -20°C. 
Semi-quantitative PCR analysis was performed by normalizing to the relative 
amount of cDNA of a house-keeping gene. For this purpose, elongation factor 2 
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(EF-2) and the ribosomal protein L32 (Rpl32) were chosen as intern controls for 
the rSMCs and HUVECs, respectively. The reagents for PCR amplification were 
premixed to ensure identical conditions in each reaction [20 mM Tris/HCl (pH 8.4), 
1.5 mM MgCl2, 0.2 mM dNTP, 20 pmol primers (for both forward and reverse 
primers) and 1 U Taq DNA polymerase, in a total volume of 50 µl]. The PCR 
reaction was performed in a model thermocycler (Biometra, Goettingen) 
programmed as follows:  
Pre-denaturation: 2 min at 94°C  
Denaturation:  30 sec at 94°C  
Annealing:  45 sec at the temperatures shown in Table 2 
Extension:  1 min at 76°C  
Cycles:   primer-specific number as shown in Table 2 
Final extension: 5 min at 76°C  
After the amplification, PCR products were separated on 1.5% agarose gels with 
ethidium bromide staining. The density of the detected bands was determined by 
using PhotoFinish® imaging system (WordStar Atlanta Technology Center, USA) 
and One-Dscan® (software, Scananlytics, Billerica, USA).  
 












































Materials and methods 
The identity of the PCR products was confirmed by sequencing as described in 2.1.7. 
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2.4         Rat colitis model 
 
Rat CD40 antisense ODNs were administrated to TNBS/ethanol treated rats 
according to the study protocol (Fig. 4). Its therapeutic effects were evaluated by 





















Non-fasted male Wistar rats (Winkelmann, Borchen/Westfalen, Germany) 
weighting 200-250 g were used for the experiments. All animals were fed standard 
rat chow and had free access to water and food. The animals were kept according 
to the German legislation on the protection of animals with a 12 h day and night 
rhythm. 
 
2.4.2 The TNBS-induced colitis model of the rat 
The inducing mixture was prepared by dissolving 20 mg TNBS (Sigma, 
Heidelberg) in 35% ethanol with 0.9% NaCl in a total volume of 136 µl. Rats were 
placed under light ether anaesthesia. The mixture was applied by an intracolonic 
injection through an 8 cm long catheter inserted through the anal canal into the 
descending colon. Expelling of the total volume was ensured by additional air 
injection. After removing of the catheter, rats were holding in a headfirst position for 
30 sec to avoid flowing out of the enema. Rats were kept in normal condition after 
the intervention.  
For application of the antisense and scrambled ODNs, the mixture of ODNs and 
liposome (novosom® AG, Halle) was prepared freshly and applied 4 hours prior to 
the TNBS/ethanol enema via the same route.  
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2.4.3 Macroscopic analysis 
Seven days after induction of colitis, the animals were sacrificed in deep ether 
anaesthesia. The colon was removed and opened longitudinally. Colonic 
inflammation and damage were assessed by macroscopic evaluation. This was 
done using a score originally described by McCafferty et al. (1994) with some 
modifications (Table 3).  
 
























Severe (necrosis at two or more sites or extending >1 cm) 4 
Ulceration  
Normal appearance 0 
Focal hyeremia, no ulcers 1 
Ulceration without hyperemia or bowel wall thickening 2 
Ulceration with inflammation at one site 3 







Total score 0 – 17 
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2.4.4 Semi-quantitative RT-PCR analysis 
Total RNA was extracted from the affected part of the descending colon as well as 
from unaffected sites of the ascending colon of each animal. CD154 and VCAM-1 
mRNA expression were checked by semi-quantitative RT-PCR analysis using the 
house-keeping gene, EF-2, as an internal control. The procedure was as 
described in 2.3.2.  
 
2.4.5 Histological analysis 
Histological analyses of both the ascending and descending colon of each animal 
were done as follows. Tissue samples were freshly fixed with 4% formaldehyde in 
PBS (pH 7.4) for 12 hours. Then the samples were trimmed into proper size and 
dehydrated by subsequently passing through 75% (twice), 95% (twice) and 100% 
(three times) alcohol for 2 h each. Clearing of alcohol from the tissue was 
performed using xylol. Then, specimens were embedded in liquid paraffin (55°C). 
After solidification 5 µm thick sections were cut and mounted onto ‘Superfrost plus’ 
glass slides (Menzel-Glaeser, Braunschweig). For paraffin removal, sections were 
allowed to dry at 60°C for 1 h. Then, slides were subsequently placed in xylol for 
2× 7 min, propanol for 5 min, 98% alcohol for 5 min, 75% alcohol for 5 min, 60% 
alcohol for 5 min and finally distilled water for 5 min. 
Hematoxylin/eosin staining: After the dewaxing, sections were stained for 5 min 
in hematoxylin and eosin solution (Merck, Darmstadt) each. After passing through 
60%, 75%, 98% alcohol, propanol and xylol (twice), the slides were fixed with 
cover-slips. The colonic damages of each section were blindly assessed under 
microscope according to the criteria described in Table 3. 
Immunohistological staining: For immunohistological staining, the sections were 
incubated 6 times for 5 min in 0.01 M citrate buffer (pH 6.0) in a microwave oven 
set to high power (800 W). Thereafter, they were incubated in 3% hydrogen 
peroxide for 15 minutes to block endogenous peroxidase activity. Then, the 
sections were incubated for 1 h with blocking buffer (10% BSA in PBS), followed 
by an overnight incubation at 4°C with a mouse anti-rat ED-1 antibody (1:750 
dilution, Dako, Hamburg) or mouse anti-rat CD3 antibody (1:75 dilution), 
respectively. To visualise the bound primary antibody, the following detector 
components were applied at the recommended working dilutions of the 
manufacturer (Dako, Hamburg): biotinylated secondary mouse-anti-goat/sheep or 
19 
Materials and methods 
swine-anti-rabbit antibody as a linker, peroxidase-conjugated avidin as a label and 
3-amino-9-ethylcarbazole as a chromogen. 
Granulocyte staining: Granulocytes were specifically stained by using the 
Esterase Kit (Sigma Diagnostics, Louis, USA). Cellular esterases are ubiquitous, 
apparently representing a series of different enzymes acting upon select 
substrates. Under defined reaction conditions, it is possible to distinguish 
granulocytes from other cell types, using specific esterase substrates. The staining 
solution was prepared freshly as follows: 1 ml sodium nitrite solution (0.1 mol/L) 
was gently mixed with 1 ml Fast Red Violet LB Base solution (15 mg/mL, in 0.4 
mol/L hydrochloric acid with stabilizer) and incubated for 2 min at 37°C. Thereafter, 
the mixture was dissolved in 40 ml pre-warmed deionised water and subsequently 
adding 5 ml TRIZAMAL buffer (1 mol/L with surfactant, pH 6.3) and 1 ml naphthol 
AS-D chloroacetate solution (8 mg/mL with stabilizer). The dewaxed sections were 
incubated in the staining solution for 15 min at 37°C protected from light and then 
rinsed thoroughly in deionised water for 5 min. After counterstained with 
hematoxylin for 2 min followed by rinsing in tap water, the slides were fixed with 
cover-slips. 










Severe  3 
Depth of lesion   
None  0 
Superficial  1 
One third 2 
Two third 3 
Transmural  4 
Fibrosis   
None  0 
Minor 1 
Major 2 
Lymphocyte infiltration  
No  0 
Yes  1 
Total score  0 – 12 
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2.5 Statistical analysis 
Unless indicated otherwise, all data in the figures and text are expressed as 
means±s.e. of n independent observations (i.e., samples from different animals). 
Statistical evaluation was performed either by one-way analysis of variance 
followed by Bonferroni multiple comparisons test (comparison of three or more 
groups) or unpaired two-tailed Students t-test (comparison of two groups) where 
appropriate with the Instat for WindowsTM statistics software package (GraphPad 




3.1 Sequencing of the rat CD40 gene 
To be able to design an antisense ODN against rat CD40 mRNA, first the 5’-end of 
this RNA had to be characterized as the gene sequence was not available from 
public data base in GenBank. A partial sequence located in the middle part of rat 
CD40 mRNA, was previously sequenced in our group (Krzesz R. et al. 1999). 
Based on the known sequence, three specific primers were designed (as shown in 
2.1). Using the total RNA extracted from rat spleen as a template, the 5’-end of rat 
CD40 mRNA was subsequently amplified by using the 5’-RACE method.  
As shown in Fig. 5, although no specific band was detected after the first round of 
PCR (lane 1), using the dilution (1:500) of this PCR product as a template, a band 
of about 400 bp appeared after the nested PCR (lane 2). The identity of this 
fragment was confirmed by running a control PCR (lane 3). Thus, the expected 
220 bp fragment could be amplified with a pair of rat CD40 primers. Then, the 400 
bp fragment was purified from the nested PCR product after running an agarose 
gel and sequenced with a rat CD40 primer (rGSP3). The result is shown in Fig. 6. 
It revealed that this fragment contains 220 bp same sequence of the previously 
known region of rat CD40 mRNA. Moreover, it shares 86% homology with mouse 
CD40 gene, thus further confirmed it as the sequence of rat CD40 gene.  
                                                  M         1          2          3 
500 bp
 
Figure 5. Specific amplification of rat CD40 by 5’-RACE. Using the total RNA from 
rat spleen as a template, 5’-end unknown region of rat CD40 was amplified by the 5’-
RACE method. The PCR products from different steps were separated on a 1.5 % 
agarose gel. M: 100 bp length DNA Marker; 1: Products from the first PCR using rGSP2 
and abridged anchor primer (AAP); 2: Products from the nested PCR using rGSP3 and 











































































































































































































































































































































































































































































































































































After obtaining the 5’-end of rat CD40 mRNA, antisense ODNs were generated 
from different locations along this region (Table 4). Selection criteria were as 
follows: The antisense ODN should posses 16 - 19 bases with a guanine/cytosine 
(GC) content between 40% and 65%. To avoid destruction in lysosomes and 
degradation by the various endo- and exonucleases present in the course of 
experiments, the ODNs were protected by nuclease-resistant phosphorothioate 
bonds in the last three nucleotides at the 5’- and 3’-end, respectively.  
 
Table 4. Antisense ODN against rat CD40 mRNA (including the scrambled control). 
ODN name Sequence Location 
rAS1    *G*GCAGCATTGCA*G*A* -6  +10 
rAS2    *C*GCTGTCAACAAGCA*G*C* +35  +53 
rAS3    *C*TAGATGGACCGCT*G*T* +46  +63 
rAS4    *A*CACACTGTCCT*A*G* +58  +73 
rAS5    *T*CCCTGTTCCAG*T*G* +208  +223 
rScr     *C*TCACGTCGAGGTG*T*A* Scrambled ODN 
* phosphorothioate modified nucleotide 
 
3.3 Effects of CD40 antisense ODN in rat vascular smooth muscle cells 
(rSMCs) 
3.3.1 Functional expression of CD40 in rSMCs 
In cultured rSMCs, a certain level of CD40 expression was detected under basal 
conditions. This CD40 expression was markedly increased by stimulation with 
TNF-α (1000 U/ml) plus IFN-γ (100 U/ml). Interestingly, CD40 stimulation itself 
(through CD154) also up-regulated CD40 expression on both the mRNA and 
protein level (Fig. 7). It has been reported that CD40 activation enhances the 
expression of adhesion molecules and pro-inflammatory cytokines, including 
VCAM-1, E-selectin and MCP-1 in vascular smooth muscle cells (van Kooten and 
Banchereau 2000). Therefore, rSMCs were chosen as target cells and CD40-
mediated VCAM-1 expression as read-out to judge the effects and specificity of 




A. RT-PCR B. Western blot 
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 β-actin EF-2 
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−         −          +          CD154 
 
Figure 7. CD40 expression in rSMCs. (A) The cells were stimulated with TNF-α 
(1000 U/ml) plus IFN-γ (100 U/ml) or co-cultured with CD154+ P3xTB.A7 cells (2×106 
cells/ml) for 12 h. CD40 expression was measured by semi-quantitative RT-PCR, using a 
EF-2 mRNA as an internal control. (B) CD40 protein expression in rSMCs was measured 
by Western blot analysis 24 h after the stimulation. The equal loading of each sample was 
verified by reprobing the membrane with an anti-β-actin antibody. The relative intensity (% 
of control) was measured by densitometry, indicated at the top. The figure depicts the 
result of one representative experiment. Similar results were obtained in 2-3 additional 
experiments with different batches of rSMCs. 
 
 
3.3.2 Effects of the different antisense ODNs on CD40 expression 
With the help of Lipofectin, the antisense ODNs were transfected into rSMCs. 
Their effect on CD40 expression was measured at the protein level. As expected, 
antisense ODNs against the different regions of rat CD40 mRNA showed different 
efficiency (Fig. 8). The rAS1, encompassing the transcription initiation codon, was 
inactive and rAS5 had no effect either. The other three antisense ODNs tested in 
this study showed significant inhibition on CD40 expression as compared to the 
untreated control. Especially, rAS3, which encompasses position +46 to +63 of the 
rat CD40 mRNA, effectively inhibited CD40 expression. Its blocking effect on 



































Cont. rAS1 rAS2 rAS3 rAS4 rAS5 
Figure 8. Effects of the different antisense ODNs on CD40 expression. The 
cultured rSMCs were transfected with different antisense ODNs at the same concentration 
(1 µM). Cells were harvested 24 h after transfection for Western blot analysis. CD40 
expression was estimated by densitometry and expressed as relative intensity (%) 
compared with untreated cells. The statistical summary of the effects of the different 
antisense ODNs on CD40 expression is shown on the left (n=3, ∗P<0.01 versus untreated 
control). A typical Western blot result is shown on the right. The equal loading of each 
sample was verified by reprobing the membrane with an anti-β-actin antibody. 
 
3.3.3 Characterization of the blocking effects of CD40 antisense ODNs 
Subsequently, rSMCs were transfected with different concentrations of rAS3 (200, 
400, 600, 800 and 1000 nM). Changes in CD40 expression were monitored as 
described above. It was found that rAS3 inhibited CD40 expression in a 
concentration-dependent manner. A significant inhibition was observed even at the 
lowest concentration (200 nM) tested in this experiment (50.5% ± 6.2% of 
untreated control). At a concentration of 1000 nM, rAS3 achieved 85% reduction of 
CD40 expression compared with the untreated control (Fig. 9A). Moreover, to 
study the stability of the blocking effect, the rSMCs were transfected with rAS3 
(1000 nM) and the change in CD40 expression was measured for up to 6 days 
after transfection. It was found that the inhibition of CD40 expression maintained 
the same level for three days (Fig. 9B). The effect appeared to diminish on the 
fourth day probably due to nuclease degradation of the antisense ODN and/or 
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3.3.4 Inhibition of CD154-induced VCAM-1 expression in rAS3-treated 
rSMCs 
Having established that rAS3 has the most potent inhibitory effect on CD40 
expression, investigations were extended to determine whether it could 
functionally block CD40 activation in rSMCs. In these experiments, VCAM-1 
expression was used as a read-out for CD40 stimulation. Moreover, CD40 is a 
member of the TNF-receptor family and, as such, shares some common signaling 
pathways with the TNF-α receptor. To demonstrate the specificity of rAS3 for the 
CD40 pathway, its effects on TNF-α-mediated activation were also measured. A 
scrambled ODN was used as a control to indicate any nonspecific effects. As 
shown in Fig. 10, VCAM-1 expression in the rSMCs was markedly increased after 
stimulation with TNF-α (1000 U/ml) or CD154. After treatment with rAS3, CD154 
stimulated VCAM-1 expression was significantly inhibited, while the scrambled 
ODN had no effect. Furthermore, neither rAS3 nor the scrambled ODN had any 
effect on TNF-α induced VCAM-1 expression, indicating a highly specific effect of 
rAS3 on the CD40 signaling pathway. These results verify that rAS3 is a specific 
blocker for CD154/CD40 interactions, and encouraged us to investigate its 



























Figure 10. Blocking effect of rAS3 on CD40-dependent VCAM-1 expression in 
rSMCs. The cells were transfected with rAS3 or rScr (1 µM). After 24 h, they were 
stimulated with TNF-α (1000 U/ml) or by co-culturing with CD154+ P3xTB.A7 cells (2×106 
cells/ml) for 12 h. VCAM-1 mRNA abundance was measured by semi-quantitative RT-
PCR, using EF-2 as an internal control. Statistical summary of VCAM-1 mRNA abundance 
is expressed as percentage of the CD154-stimulated control (n=3-5, ∗P<0.01 versus 
control in the same group).  
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3.4 Therapeutic effects of the CD40 antisense ODN in TNBS-induced 
colitis 
To further study the therapeutic effects of the CD40 antisense ODNs in vivo, rAS3 
was administrated in the TNBS-induced colitis model of the rat. Previous research 
in our group has shown that a single enema consisting of 20 mg TNBS in 35% 
ethanol reproducibly induces a transient Crohn’s disease-like colitis in Wistar rat. 
In this model, the maximum inflammatory response was observed at day 3 to 5 
and spontaneous healing occured after approximately 4 weeks. Enhanced 
expression CD154 could be detected in the affected mucosa, indicating the 
involvement of CD154/CD40 interactions in the inflammatory reaction 
(Lienenlueke et al. 2001). For this study, the CD40 antisense ODNs (rAS3) and 
the scrambled control ODNs (rScr) were packed into liposomes (novosom®AG) and 
administrated by intra colonic injection 4 h before the TNBS/ethanol enema. The 
degree of inflammation and damage to the colon was evaluated 7 days post colitis 
induction by macroscopic scoring (as described in the methods section, see also 
Lienenlueke et al. 2001), histological staining, immunohistochemistry and RT-PCR 
analysis. 
 
3.4.1 CD40 antisense treatment prevents the development of severe colitis 
Seven days after the administration of TNBS/ethanol, significant edema formation 
together with focal ulcerations, necrosis and adhesion was observed in the 
descending colon of almost all control animals. In the rAS3 treatment group, 
however, the overall damage to the colon (macroscorpic score) was significantly 
reduced as compared to the untreated group (Table 5). 
Table 5. Effects of rat CD40 antisense ODNs on macroscopic appearance. Stated are 
the mean ± s.e. score values rounded to one decimal. (∗P<0.01 versus no treatment) 
Parameter (range) 
 
No treatment rAS3 treatment rScr treatment 
Diarrhea (0-2) 0.1 ± 0.4 0.0 ± 0.0 0.4 ± 0.5 
General condition (0-1) 0.3 ± 0.3 0.0 ± 0.0 0.0 ± 0.0 
Adhesions (0-3) 2.1 ± 0.6 1.0 ± 0.5∗ 2.1 ± 0.7 
Perforation (0-1) 0.3 ± 0.5 0.0 ± 0.0∗ 0.4 ± 0.5 
Necrosis (0-4) 2.9 ± 0.6 1.3 ± 1.3∗ 3.4 ± 0.5 
Ulceration (0-4) 3.6 ± 0.5 2.5 ± 0.5∗ 3.9 ± 0.4 
Edema (0-1) 1.0 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 
Megacolon (0-1) 0.3 ± 0.5 0.1 ± 0.4∗ 0.3 ± 0.5 
Total score  10.6 ± 2.3 5.9 ± 2.2∗  11.6 ± 2.4 
Number of animals 8 8 7 
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Of note was that a significant reduction in the most severe types of damages i.e. 
necrosis, ulceration and adhesion, as well as a decrease in perforation and 
megacolon formation, was observed in the rAS3 treatment group. On the other 
hand, treatment with the scrambled control ODN (rScr) did not result in any 
improvement regarding the colonic inflammation. 
Histologically, damage to the bowel wall appeared to be discontinuous with areas 
of normal mucosa next to severely necrotic ones. Sections from each sample were 
evaluated according to the criteria described in 2.4.5 after haematoxylin/eosin 
staining (Fig.11). In affected areas, the mucosa propria was usually lost and the 
bowel wall was thickened because of the prominent infiltration of leukocytes and 
moderate fibrosis (Fig. 12B). Treating rats with rAS3, but not with rScr, resulted in 
a significant improvement in colonic inflammation. The pathological changes in 
bowel wall structure of rAS3-treated animals were much less and usually showed 






















Figure 11. Effects of rat CD40 antisense ODN on microscopic appearance. 
Sections from the affected descending colon of each animal were stained with 
hematoxylin/eosin. Inflammation and damage of the bowel wall were evaluated according 
to the criteria described in 2.4.5. Treatment of CD40 antisense ODN (rAS3) but not the 
scrambled control ODN (rScr) significantly attenuated the development of inflammation in 








Figure 12. Histological analysis of CD40 antisense ODN effects in TNBS-induced 
colitis 7 days after the enema. Normal structure of the bowel wall in the unaffected 
ascending colon (A), but major changes in the affected descending colon of control 
animals (B), revealed by necrosis and thickening of bowel wall as well as a prominent 
leukocyte infiltrate. Treatment with rAS3 (D), but not with rScr (C), resulted in a significant 
protection against colitis development. Representative histology data from each group; 
n=7-8; hematoxylin/eosin staining; original×50. 
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Furthermore, immunohistochemistry results revealed the prominent infiltration of 
granulocytes in the affected colon of both control and rScr-treated rats, especially 
in the most severe damaged region (Fig.13B, C, respectively). In contrast, in 
colonic sections from rAS3-treated animals, only few granulocytes were observed 
in the mucosa and submucosa propria (Fig.13D). However, CD3 positive-stained 
cells (T-cells) were mostly located in the less inflamed regions. No significant 
decrease of these cells was observed with the rAS3-treatment, as judged by 
immuno- histochemistry (Fig. 14).  
 
 
Figure 13. CD40 antisense ODN effects on granulocyte infiltration in the colon of 
animals. The sections were stained with Fast Red Violet LB (Sigma Diagnostics) for 
granulocyte in bright red colour. Only a few cells were positively stained in the unaffected 
ascending colon (A), while a great number of granulocytes were observed in the 
descending colon of control animals (B). Treatment with rAS3 (D), but not with rScr (C) 
resulted in a significant decrease in the granulocytes in the affected descending colon of 





Figure 14. CD40 antisense ODN effects on T-cell infiltration in the colon of animals. 
The sections were stained with anti-CD3 antibody. Only a few cells were positively stained 
in the unaffected ascending colon (A), while a large number of CD3+ cells was observed 
in the descending colon of control (B), rScr-treated (C) and rAS3-treated animals (D). 




3.4.2 CD40 antisense ODN inhibits enhanced VCAM-1 expression in vivo 
According to RT-PCR analysis, expression of CD154 and VCAM-1 was 
significantly increased in the descending colon of TNBS-treated animals as 
compared to the unaffected ascending colon (Fig. 15A). This indicated the ongoing 
inflammatory response in TNBS-treated animals. The rAS3 treatment significantly 
reduced the increase in VCAM-1 mRNA abundance, while CD154 expression was 
not affected (Fig. 15B). In rScr-treatmed animals, both VCAM-1 and CD154 mRNA 

























































 15. Effects of CD40 antisense ODNs on VCAM-1 (A) and CD154 (B) mRNA 
ance in the colon of TNBS-treated rat. Samples of both the ascending (Asc; i.e. 
cted region) and descending colon (Des; i.e. affected region) were collected 7 days 
olitis induction. The mRNA abundance (relative to the mRNA level of the house-




3.5 Experiments with human CD40 antisense ODNs 
3.5.1 Design of human CD40 antisense ODNs 
Having demonstrated that blockade of CD40 expression by anti-rat CD40 ODNs 
led to functional effects both in vitro and in vivo, it was of special interest if 
antisense ODN-mediated CD40 suppression was also effective in human cells. 
The sequence of human CD40 cDNA was obtained from GenBank (Genbank No. 
X60592). Similar to the design of rat CD40 antisense ODNs, several antisense 
ODNs were selected from the 5’-end of the mRNA (Tab. 6). The antisense ODNs 
were 16 – 18 bases in length and flanked by three phosphorothioate modified 
nucleotides at both ends to provide more resistance against nucleases. 
 
Table 6. Antisense ODNs (including the scrambled control) against human CD40. 
Human CD40 Sequence ocation 
hAS1  GGCGGCAGGAC*C*A*  28  -11 
hAS2   G ACG AAC CA*T*G*  1  +15 
hAS3   GTCAGCAAGCA*G*C*  35  +52 
hAS4   AGTGGGTGG*T*T*  60  +75 
hAS5   ACTGTTTATTA*G*G*  93  +110 








* phosphorothioate modified nucleotide 
 
 
3.5.2 Blocking effects of human CD40 antisense ODNs in human endothelial 
cells 
For checking effects of these human CD40 antisense ODNs, primary cultured 
human umbilical vein endothelial cells (HUVECs) were selected as the target cell. 
As noted in the introduction, though basal expression of CD40 in endothelial cells 
is usually low, expression of the gene is markedly induced under pro-inflammatory 
conditions (especially with TNF-α 100 U/ml plus IFN-γ 1000 U/ml). This stimulation 
of CD40 expression occurs at the transcriptional level. The effects of human CD40 
antisense ODNs were investigated both under basal and pro-inflammatory 
conditions in this study. As in rSMCs, not all antisense ODNs showed the same 
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effects on CD40 expression (Fig. 16). Among them, the hAS4 encompassing +60 
to +75 of the human CD40 mRNA, showed the most potent inhibition under both 
basal as well as stimulated conditions. The other antisense ODNs either had no 










































     
Cont.       hAS1      hAS2              Cont.        hAS3        hAS4        hAS5        Treatment 
−    +     −     +    −    +          −    +     −    +     −    +     −     +      TNFα/IFNγ 
re. 16 Effects of CD40 antisense ODNs on CD40 expression in HUVECs. The 
red HUVECs were transfected with the antisense ODNs (400 nM) and then 
ulated with TNF-α (100 U/ml) plus IFN-γ (1000 U/ml) or left untreated. Changes in 
0 expression were measured by Western blot analysis after 24 h. (A) CD40 
ession is shown in relative intensities (% of treated control, mean of two experiments). 
Representative result of Western blot analysis. Equal protein of each sample was 
ied by reprobing the membrane with an anti-β-actin antibody. 
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Further application of hAS4 at different concentrations revealed a concentration-
dependent decrease in CD40 expression both under basal and stimulated 
conditions (Fig. 17). Significant inhibition was attained already at a concentration 
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Figure. 17 CD40 expression in human endothelial cells after hAS4 transfection. 
The cultured HUVECs were transfected with different concentrations of hAS4. Basal 
CD40 expression (A) as well as TNF-α (100 U/ml) plus IFN-γ (1000 U/ml) stimulated 
CD40 expression were measured by Western blot analysis after 24 h. CD40 expression is 
expressed as percentage of that in untransfected control cells. (n=3, ∗P<0.01 vs. 
untransfected control). Equal protein loading of each sample was verified by reprobing the 
membrane with an anti-β-actin antibody.  
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3.5.3 Inhibition of CD154-mediated IL-12 p40 expression in hAS4-treated 
HUVECs 
With the establishment of the most potent antisense ODN against human CD40, 
the study was continued by evaluating its blocking effects on CD40 function. 
Activation of CD40 in HUVEC enhances the expression of adhesion molecules 
(ICAM-1, VCAM-1 and E-selectin), tissue factor and the release of cytokines and 
chemokines (IL-6, IL-8 and MCP-1). Notably, CD154 also stimulates expression of 
IL-12 p40, which forms a heterodimer with IL-12 p35 and plays an essential role in 
the differentiation of Th1-cells. This stimulated IL-12 p40 expression can be further 
enhanced by IFN-γ. Interestingly, de nove IL-12 p40 expression appears to be a 
special feature of CD154 stimulation in HUVEC, since TNF-α, which belongs to 
the same superfamily as CD154, has no such effect (Fig. 16). Therefore, IL-12 p40 
was selected as a read-out for CD40 function in HUVEC.  
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Figure 18. IL-12 p40 
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Figure 19. Effect of CD40
HUVECs.  Cells were transfe
were co-cultured with CD154+
of IFN-γ (1000 U/ml) for 12 h
RT-PCR, using Rpl32 as the 
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In recent years, there is increasing evidence that CD154/CD40 interactions are 
involved in the pathogenesis of many autoimmune diseases, where T or B cells 
have a prominent role. As noted above, administration of anti-CD154 antibodies 
has been demonstrated to effectively inhibit inflammatory responses in a variety of 
animal models. Although it has been reported that these antibodies only need to 
be administrated over a short period of time, major thromboembolic complications 
have been reported for this treatment both in experimental animals (Kawai et al. 
2000) and in patients (Vincent 1999). In addition, the humanized antibodies are 
expensive to produce and prolonged use can lead to sensitization and 
concomitant loss of therapeutic effect. It would be helpful, therefore, to provide 
other means of interfering with CD154/CD40 interactions. 
The approach of targeting CD40 expression in CD154-responsive cells may 
provide such an alternative. However, low-molecular weight antagonists for CD40 
are not yet available and antibodies against CD40 activate rather than inhibit 
CD154 signaling (Sakata et al. 2001). Here, the possibility of blocking 
CD154/CD40 pathway with CD40 antisense ODNs was examined. 
 
4.1 Antisense technology  
Antisense molecules are usually short, 15-25 bases long, single stranded DNA 
molecules, which comprise the complementary sequence against their target 
mRNA. The specificity of antisense molecules has been reported to be extremely 
high so that translation of two mRNAs that differ by mutation of a single base can 
be differentially inhibited (Monia et al. 1992). This qualifies antisense ODNs as an 
ideal tool to mechanistically dissect one pathway from the multitude pathways 
involved in chronic inflammatory diseases. In this study, the antisense technology 
was employed for blocking CD40 expression and thus interfere with CD154/CD40 
interactions.  
To know the sequence of a target mRNA is the first requirement for antisense ODN 
design. Unfortunately, the complete rat CD40 mRNA sequence was not available 
in GenBank. Moreover, it has been reported that multiple isoforms of CD40 mRNA, 
generated by alternative splicing, exist in both human and mouse (Tone et al. 
2001). This may also happen to rat CD40 mRNA. The mouse CD40 splicing 
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variances occur in the region between exon 5 and exon 9 of the gene. The major 
alternative isoform lacks the membrane-associated endodomain and seems to 
reduce the amount of the signal transducing form on the cell surface. The exact 
role of these splice variants in CD40 signaling and their distribution in other 
primary cells still need to be investigated. Therefore, we focussed on the 5’-end of 
rat CD40 mRNA and the sequence of this part was obtained by employing the 5’-
RACE method. 
Antisense molecules must arrive at their target mRNA intact to avoid destruction in 
lysosomes and degradation by the various endo- and exonucleases present 
intracellularly and within serum and tissues (Thierry et al. 1992). Several chemical 
modifications can be incorporated into antisense molecules to boost their nuclease 
resistance. Among them, the phosphorothioate-modified and 2’-O-methyl 
oligonucleotides are most commonly used. The phosphorothioate modification, in 
which one of the non-bridging oxygen atoms in the nucleotide backbone is 
replaced with sulfur, fully supports antisense activities (Mayers and Dean 2000). 
However, the mRNA binding affinity of this modified ODNs is also reduced. Here, 
the antisense ODNs were flanked on both sides by three phosphorothioated 
nucleotides to give them resistance to nuclease without interfering with their mRNA 
binding affinity too much. 
 
4.2 Application of anti-rat CD40 antisense ODNs in vitro 
Antisense ODNs were initially selected with a GC content between 40% and 65% 
from the obtained partial sequence of rat CD40. They must hybridize to target 
mRNA with sufficient affinity and specificity, and evoke a mechanism of action 
leading to mRNA inactivation or destruction. Inhibition of protein expression by 
antisense ODN is achieved by a variety of mechanisms including RNase H 
activation, transcription arrest, splicing inhibition and blocking translation (Fig.20) 
(Myers et al. 2000). The most widely recognized mechanism involves RNase H 
mediated cleavage of the target mRNA. RNase H is an endonuclease that 
recognizes RNA-DNA duplex molecules and selectively cleaves the RNA strand. 
The process is catalytic, i.e. once an RNA molecule is cleaved, the antisense ODN 
dissociates from the duplex and is free to bind to a second target mRNA (Kanaya 







Figure 20. The mechanisms by which antisense ODNs disrupt protein synthesis 
(adopted from Myers et al. 2000). (1). The blockade of ribosomal subunit attachment to 
mRNA at the 5’ cap site. (2). Interference with proper mRNA splicing through antisense 
binding to splice donor or splice acceptor sites. This should happen in the nucleus with 
hnRNA. (3) RNase H mediated degradation of DNA-mRNA hybrid. Hybridization can 
occur anywhere in the mRNA where an antisense ODN binds with sufficient affinity. 
 
In fact, antisense ODNs encompassing different region of an mRNA molecule 
usually behave differently in blocking their target gene expression. An antisense 
ODN can access and bind only to few regions of the mRNA molecule, i.e. those 
are positioned outside its three-dimensional structure. For finding out the most 
effective antisense for the rat CD40, five antisense ODNs, which hybridize to the 
different parts of the mRNA, were designed. Their blocking effects on CD40 
expression were investigated in rat vascular smooth muscle cells. One of them 
(rAS3), located at position +46 - +63 proved to be an effective inhibitor of CD40 
protein expression. A recent report on the use of antisense ODNs against porcine 
CD40 resulted in the characterization of an effective antisense ODN targeting the 
3’-untranslated region of the mRNA molecule (Rushworth et al. 2002), indicating 
that multiple antisense ODN-sensitive sites might exist in one mRNA molecule. 
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Further characterization of rAS3 showed that the antisense ODN inhibited CD40 
expression in a dose-dependent manner, attaining about 90% inhibition at a 
concentration of 1 µM. Moreover, its blocking effect on CD40 expression lasted up 
to 3 days after transfection in vitro. The transient nature of this inhibitory effect is 
presumably due to degradation of the antisense ODNs and/or the decrease in 
concentration during cell proliferation. Elucidating the time-course and required 
concentration to obtain an optimal inhibitory effect of rAS3 was important, as the 
final goal of the study was to use rAS3 as an experimental drug in vivo. However, it 
is difficult to predict how long CD40 expression must be down-regulated in vivo to 
observe therapeutic effects. Interestingly, most therapeutic stratgies using anti-
CD154 antibodies revealed that only a brief treatment regimen was necessary to 
achieve beneficial effects (Liu et al. 2000, Cong et al 2000).  
Moreover, by virtue of the decrease in CD40 expression rAS3 also blocked 
CD154/CD40 interactions functionally as demonstrated by the decrease in VCAM-
1 expression following CD154 stimulation in rAS3-transfected rSMCs. The 
specificity of rAS3 to interfere with CD154/CD40 signaling was demonstrated by its 
inability to TNF-α-induced changes in gene expression. Moreover, the inactivity of 
the scrambled control ODN demonstrated that rAS3 reduces CD40 expression 
through a sequence-dependent mechanism. Collectively these data confirmed that 
rAS3 is not only a valuable tool to specifically interfere with CD154/CD50 
interactions, but also to investigate the pathological role of CD40 in chronic 
inflammatory diseases in vivo. 
 
4.3 Application of anti-rat CD40 antisense ODNs in vivo 
In this study, the TNBS-induced rat colitis model was employed to evaluate the 
therapeutic effects of rAS3. In this model, colonic injury and inflammation are 
induced by intrarectal administration of a TNBS/ethanol enema. It is thought that 
ethanol temporarily disrupts the mucosal epithelial barrier and enables TNBS to 
bind covalently to proteins of colonic epithelial cells and modify them. 
Subsequently, these TNBS-modified self-antigens are presented to the immune 
system, leading to a delayed-type hypersensitivity reaction. The TNBS-induced 
colitis model has marked similarities to human Crohn’s disease because it is also 
characterized by Th1-cell mediated inflammation (Singh et al. 2001). The 
involvement of CD154/CD40 interactions in this colitis model has been revealed by 
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elevated expression of both CD154 and CD40 in the affected mucosa and the 
therapeutic effects achieved by administration of an anti-CD154 antibody 
(Lienenlueke et al. 2001, Stueber et al. 1996).  
For successful administration of the antisense ODNs, they must reach a sufficient 
concentration in the affected tissue. The mechanism by which oligonucleotides 
enter cells remains controversial but probably involves fluid phase pinocytosis, 
receptor-mediated endocytosis, or both (Gewirtz et al. 1996, Bennett et al. 1992). 
For most cells, delivery systems need to be used such as inactivated viruses, 
liposomes or electroporation. Antisense ODN uptake in vivo may be even more 
complex and involve different mechanisms than those in cultured cells through 
possible interactions with a variety of intra- and extracellular proteins. The usual 
route of antisense ODN administration is intravenous injection, which was used, 
e.g., in most studies employing antisense ODN against TNF-α, ICAM-1 and 
VCAM-1 in IBD models (Myers et al. 2003, Rijcken et al 2002). After intravenous 
injection, phosphorothioate-modified oligonucleotides distribute rapidly to 
peripheral tissues with high amounts going to the kidney and liver. However, a 
significant accumulation also occurs in bone marrow, skeletal muscle, skin and the 
intestine. Besides causing unexpected side effects, this wide distribution also lead 
to high costs because extremely high dosage of the antisense ODN is necessary 
for efficient therapy. In addition, DNA binding to serum proteins could lead to 
increases in blood clotting time and complement activation (Galbraith et al 1994, 
Henry et al. 1997). Therefore, local administration may offer several advantages 
including less side effects and higher local concentration of the antisense ODN. In 
this study, rAS3 was first packed into liposomes followed by administration through 
intracolonic injection.  
Single application of the liposomal antisense ODN greatly attenuated the severe 
inflammation following the TNBS/ethanol enema, as judged by both macroscopic 
and histology analysis. As noted above, CD40 is mainly expressed by APCs and 
endothelial cells, which most likely are the target cells of the antisense ODNs in 
this experiment. Change in CD40 expression in these cells, however, could not be 
revealed due to the lack of an anti-rat CD40 antibody suitable for 
immunohistochemistry. On the other hand, it is well known that CD154/CD40 
interactions between activated Th1-cells and APCs/endothelial cells in the affected 
mucosa, greatly contribute to the secretion of pro-inflammatory cytokines including 
IL-12, IFN-γ and TNF-α (Cong et al. 2000, Stueber et al, 1996). At the same time, 
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the expression of adhesion molecules on endothelial cells such as VCAM-1 is also 
enhanced. This may result from exposure to the pro-inflammatory cytokines and/or 
CD154/CD40 interactions directly. RT-PCR analysis demonstrated that the rAS3 
treatment significantly reduces the increased VCAM-1 expression in the affected 
mucosa, which in turn may have contributed to the decrease in leukocytes 
infiltration revealed by histological staining. In any case, these findings strongly 
suggest that the CD40 antisense ODN attenuates CD154/CD40 interactions in 
vivo, resulting in a decreased mucosal inflammation in this model of chronic IBD. 
 
4.4 Pathophysiological role of CD154/CD40 interactions in chronic IBD 
There is increasing evidence that CD154/CD40 interactions play a role in the 
pathogenesis of chronic IBD. In CD154 transgenic mice, lethal IBD was developed 
spontaneously and characterized by the infiltration of CD154+ T-cells and CD40+ 
cells into diseased tissues (Xu et al. 1994). Actually, in patients with Crohn’s 
disease increased numbers of T-cells expressing CD154 have been detected in 
the lamina propria and several CD40+ cells have also been found in the same 
areas (Battaglia et al. 1999). Most of these CD40+ cells co-stained with CD20, thus 
revealing them as B-cells, and only a few were CD14+ macrophages. Interestingly, 
several CD40+ cells were also positive for von Willebrand factor, an endothelial 
cell-specific marker. This finding is in line with the view that the vascular 
endothelium plays an important role in the maintenance of intestinal inflammation 
and indicates that CD154/CD40 interaction on endothelial cells may contribute to 
the pathogenesis of Crohn’s disease as well.  
The CD40-mediated interactions between APCs, T cells and endothelial cells in 
the pathogenesis of chronic IBD were summarized in Fig. 21. CD154/CD40 
interactions induce APCs to secrete an important set of cytokines and chemokines 
including IL-12, TNF-α and IL-8. Especially, IL-12 is known as the major cytokine 
governing the differentiation of CD4+T cells by promoting the differentiation 
towards Th1 subsets, of which the secretion of IFN-γ is characteristic. Interestingly, 
IL-12 itself up-regulates CD154 expression in T-cells and IFN-γ enhances CD40 
expression on APCs. Such a feed-forward loop may exist between T helper cells 
and endothelial cells as well. In addition, CD154/CD40 interactions on endothelial 
cells also induce the expression of adhesion molecules, thereby generating 
signals for the recruitment and extravasation of leukocytes at the site of 
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inflammation. Although a great portion of CD40 positive cells in the affected 
mucosa is found to be B-cells, their pathological role in IBD is still not clear. 
 
Figure 21. Pathophysiological role of CD154/CD40 interactions in IBD.  
 
An in vivo study has shown that anti-CD154 antibody (MR1) treatment prevented 
the onset and progression of colitis as revealed by abrogated leukocyte infiltration, 
decreased CD54 expression and strongly diminished mRNA levels of the pro-
inflammatory cytokines IFN-γ, TNF-α and IL-12 (Liu et al. 2000). Even with a 
delayed treatment, MR1 still led to significant clinical and histological improvement 
and down-regulated secretion of pro-inflammatory cytokines. This suggests that 
the maintenance of intestinal inflammation requires continuous or at least repeated 
CD154/CD40 interactions. However, no response to administration of anti-CD154 
antibodies was seen in an established TNBS/ethanol-induced murine colitis model 
(Stueber et al. 1996). Therapeutic effects of the CD40 antisense ODNs were only 
demonstrated by treatment prior to colitis induction in this study. It still necessary, 
therefore, to evaluate whether treatment with the antisense ODN also has a 
beneficial effect on the ongoing inflammation when this has already been initiated, 
i.e. causes regression of the symptoms. 
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4.5 Decoy technology 
Regarding the increase in CD40 expression under pro-inflammatory conditions, 
especially in endothelial cells, a decoy oligonucleotide strategy was also tested in 
the colitis model. Compared with the antisense ODN, decoy ODNs represent a 
more recently developed tool, targeting gene transcription rather than translation 
(Morishita et al. 1998). Decoy ODNs are composed of two short complementary 
DNA strands mimicking the consensus binding sequence of certain transcription 
factors (TF). Once inside the cell, decoy ODNs effectively neutralize their target 
transcription factor, thereby preventing it from inducing the expression of its target 






















Figure 22. The mechanism by which decoy ODNs disrupts gene expression. 
Under normal condition, transcription factors (TF) bind to cis elements, resulting in 
continuous activation of target gene expression. Decoy ODNs prevent the binding of 
transcription factors to their target cis elements, resulting in blockade of gene expression. 
 
Previous work in our group has shown that the transcription factor STAT-1 is a key 
molecule in mediating cytokine-induced CD40 expression in rat vascular smooth 
muscle cells (Krzesz et al. 1999). Treatment with STAT-1 decoy ODNs revealed 
profound therapeutic effects in mouse and rat models of allergen-induced asthma, 
antigen-induced arthritis and transplant rejection. However, application of STAT-1 
decoy ODNs, either in liposomal form or as naked DNA, in the TNBS-induced 
colitis model in this study failed to show any therapeutic effect. Probably, this lack 
of effect was due to the inefficient delivery of the double stranded DNA molecules. 
Decoy ODNs are thought to require nuclear localization if they are to prevent the 
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transactivation of their target genes. There is increasing evidence showing that the 
uptake of double-stranded ODNs is different from that of single-stranded ODNs 
(Mann and Dzau 2000). The development of a more efficient delivery system is 
still a great challenge in the field of synthetic ODN application in vivo. Moreover, it 
was found that increase in STAT-1 expression and activation in mucosal samples 
from Crohn’s disease is not as high as from patients with ulcerative colitis 
(Schreiber et al. 2002). At the same time, high level of suppressor of cytokine 
signaling (SOCS)-3 expression, an inhibitor of STAT activation, was observed in 
Crohn’s disease. Therefore, STAT-1 might neither be the right target molecule in 
the TNBS-induced rat colitis model nor in human Crohn’s disease. However, 
expression and activation of STAT-1 still needs to be investigated in this model. 
 
4.6 The prospect of human CD40 antisense ODN 
The possibility of blocking human CD40 expression by antisense ODNs was also 
investigated in this study. The most effective antisense ODN designed (hAS4) 
locates to position +60 to +75 of the human CD40 mRNA. It significantly inhibited 
CD40 expression under both basal and pro-inflammatory conditions and could 
further down-regulate of CD154-stimulated IL-12 expression in primary cultured 
human endothelial cells. Up to now, there is only one therapeutic antisense ODN 
that has been approved for therapeutic use by the Food & Drug Administration in 
the U.S.A. This antisense ODN is complementary to the major immediate early 
region 2 of cytomegalovirus (CMV) and has been shown to be an effective against 
CMV-induced retinitis in AIDS patients (de Smet et al. 1999). However, there are 
approximately 15 other antisense ODNs in various stages of clinical development 
that are directed against cancer, inflammation and viral targets. In patients with 
Crohn’s disease, an antisense ODN against ICAM-1 (ISIS 2302) has been 
evaluated considering the importance of adhesion molecules in maintaining the 
inflammatory reaction. Although the first-in-man study failed to demonstrate 
efficacy, pharmacodynamic modeling suggests that this antisense ODN may be an 
effective therapy for steroid-dependent Crohn’s disease (Yacyshyn et al 2002). 
The evaluation of higher doses of ISIS 2302 in Crohn’s disease is currently 
underway. Moreover, an antisense ODN against protein kinase A, which is 
currently in phase II clinical trial for the treatment of cancer, has recently been 
reported to have anti-tumor activity in mice with oral delivery (Tortora et al. 2000). 
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Because drug delivery is touted as the biggest hurdle to the general use of 
antisense ODNs as effective drugs, these developments are particularly exciting. It 
would perhaps be worthwile to evaluate this delivery system with CD40 antisense 




CD154/CD40 interactions play a pivotal role both in humoral and cellular immune 
responses and, as such, represent an attractive target for immune modulation in a 
number of diseases. Over recent years, administration of anti-CD154 antibodies 
has been shown to effectively inhibit inflammatory responses in a variety of animal 
models such as collagen-induced arthritis, experimental allergic encephalomyelitis, 
murine lupus erythematosm, or experimental colitis in SCID mice. However, it has 
recently been reported that platelets present CD154 on the cell surface within 
seconds of thrombin activation in vitro and in the process of thrombus formation in 
vivo. Especially, soluable CD154 (shed from CD154-expressing cells including 
thrombocytes) is required for stabilization of existing thrombi. These may be 
relevant to the unusually high incidence of thromboembolic complications 
observed in anti-CD154 antibody treated animals and patients alike. In this study, 
an alternative approach to blocking CD154/CD40 interactions by employing a 
CD40 antisense oligonucleotide (ODN) was explored.  
After obtaining the sequence of rat CD40 mRNA by 5’-RACE (rapid amplification 
of cDNA ends), five antisense oligoneclotides were designed against different 
regions of the target mRNA. One of them (rAS3, targeting position + 46 to + 63 of 
rat CD40 mRNA) proved highly efficient at a relatively low dose in attenuating 
CD40 expression in rat cultured vascular smooth muscle cells. Its effect lasted for 
about three days in vitro. Moreover, inhibition of CD40 expression by rAS3 also led 
to a significant decrease in CD154-stimulated pro-inflammatory gene expression 
(e.g. vascular cell adhesion molecule-1, VCAM-1) in these cells. The inability of 
rAS3 to block tumor necrosis factor-α induced changes in gene expression 
validated it as a specific blocker for CD154/CD40 interactions. 
The potential therapeutic effect of the CD40 antisense ODN was investigated 
further in a Crohn’s disease-like colitis model in rats. Single treatment with the 
antisense ODN strongly attenuated the trinitrobenzene sulphonic acid/ethanol- 
induced colonic inflammation in this model. RT-PCR analysis demonstrated that 
the antisense ODN treatment significantly reduced the increase in VCAM-1 
expression in the affected mucosa, which in turn may have contributed to the 
decrease in leukocyte infiltration. 
Furthermore, an efficient antisense ODN approach against human CD40 (hAS4) 
was also designed in this study. Due to its inhibition of CD40 expression, hAS4 
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attenuated CD154-stimulated interleukin-12 p40 expression in human umbilical 
vein cultured endothelial cells. When compared to anti-CD154 antibodies, CD40 
antisense ODNs may provide the following advantages: (1) no thromboembolic 
complications; (2) ease of handling; (3) improved stability; and (4) low costs. 
In summary, the results of this study suggest that CD40 antisense ODNs interfere 
with CD154/CD40 interactions with high potency and specificity both in vitro and in 
vivo. Therefore, they may provide an attractive therapeutic approach for Type I T 
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